Early antiplatelet and antithrombotic therapy in patients with a history of recurrent miscarriages of known and unknown aetiology

Successful management of a planned pregnancy in severe congenital thrombotic thrombocytopaenic purpura: the Upshaw–Schulman syndrome

“…Although LMW heparin and low‐dose ASA may not be seen as standard care in this setting, we decided to administer these agents as prophylaxis to our patient throughout her pregnancy based on the experience of Scully and co‐workers and others (Ezra et al , 1996; Proia et al , 2002; Scully et al , 2006). This regimen has also been found to be safe and effective in patients with a history of recurrent miscarriages of known and unknown aetiology (Tzafettas et al , 2005).…”

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

“…288,289,[294][295][296][297][298][299][300][301][302] Gris et al 297 reported that enoxaparin in women with factor V Leiden, the prothrombin gene mutation, or protein S defi ciency and one previous pregnancy loss increased the live birth rate (86%) compared with low-dose aspirin alone (29%); however, the methodology and results of this randomized trial have generated much controversy, 300,303-305 and we have not included it in the evidence we used to make recommendations. A subsequent cohort study found the live birth rate of subsequent pregnancies after a single pregnancy loss at or later than 12 weeks gestation in carriers of factor V Leiden or the prothrombin mutation was, without intervention, 68% (95% CI, 46%-85%).…”

Effects of low molecular weight heparin and heparin-binding epidermal growth factor on human trophoblast in first trimester

“…It is now the most commonly used anticoagulant for patients with RSA and thrombophilia (4). In 2005, Tzafettas et al (5) reported that the success rate was high (85.1%) in 27 patients with RSA of unknown etiology after administering LMWH. This revealed that LMWH may protect the embryo by different mechanisms than anticoagulation.…”